Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

48 results
Display

Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism

Li SS, Ma J, Wong AS

Ovarian cancer is most deadly gynecologic malignancies worldwide. Chemotherapy is the mainstay treatment for ovarian cancer. Despite the initial response is promising, frequent recurrence in patients with advanced diseases remains...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Autophagy and urothelial carcinoma of the bladder: A review

Chandrasekar T, Evans CP

The incidence of urothelial carcinoma of the urinary bladder (bladder cancer) remains high. While other solid organ malignancies have seen significant improvement in morbidity and mortality, there has been little...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Silencing of ABCG2 by MicroRNA-3163 Inhibits Multidrug Resistance in Retinoblastoma Cancer Stem Cells

Jia M, Wei Z, Liu P, Zhao X

To investigate the function and regulation mechanism of ATP-binding cassette, subfamily G, member 2 (ABCG2) in retinoblastoma cancer stem cells (RCSCs), a long-term culture of RCSCs from WERI-Rb1 cell line...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
2,3,7,8-Tetrachlorodibenzo-P-Dioxin Induced Cell-Specific Drug Transporters With Acquired Cisplatin Resistance in Cisplatin Sensitive Cancer Cells

Gotovdorj , Lee E, Lim Y, Cha EJ, Kwon D, Hong E, Kim Y, Oh MY

2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) can induce drug transporter genes such as the ATP-binding cassette G member 2 (ABCG2), which contributes to multidrug resistance. We investigated the effect of TCDD pretreatment on drug...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Changes in Protein Expression in Breast Cancer after Anthracycline-Based Chemotherapy

Lee HC, Lee JO, Park IA

  • KMID: 1521665
  • Korean J Pathol.
  • 2007 Jun;41(3):165-170.
Background : Anthracyclines are the standard agents used to treat patients with advanced breast carcinoma. Some molecules are reportedly associated with anthracycline resistance; however, there has been some controversy surrounding...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Two Lung Masses with Different Responses to Pemetrexed

Park KY, Jung JW, Nam SB, Lee HJ, Kim HS, Choi YH, Lee JC

We described here a patient who had two lung masses. Although the two masses had the same histology and a similar good response to initial chemotherapy with gemcitabine and carboplatin,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Suppression of multidrug resistance via inhibition of heat shock factor by quercetin in MDR cells

Kim SH, Yeo GS, Lim YS, Kang CD, Kim CM, Chung BS

  • KMID: 754993
  • Exp Mol Med.
  • 1998 Jun;30(2):87-92.
MDR1 promoter has been shown to contain heat shock elements (HSE), and it has been reported that FM3A/M and P388/M MDR cells show a constitutively activated heat shock factor (HSF), suggesting that...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer

Takekuma M, Kuji S, Tanaka A, Takahashi , Abe M, Hirashima

OBJECTIVE: The concept of platinum sensitivity and cross-resistance among platinum agents are widely known in the management of recurrent ovarian cancer. The aim of this study was to evaluate two...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Detection of single nucleotide insertion of BCR/ABL region in imatinib-resistant human myelogenous leukemia SR-1 cells

Park TH, Kwon HC, Kim HJ, Han JY, Jeong JS, Han H, Seo CY, Kwak JY, Park JI

  • KMID: 1089462
  • Exp Mol Med.
  • 2005 Oct;37(5):507-511.
Imatinib mesylate is a selective Bcr/Abl kinase inhibitor and an effective anticancer agent for Bcr/Abl-positive chronic myelogenous leukemia. Most patients in chronic phase maintain durable responses; however, many in blast...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
LRIG1 Enhances Chemosensitivity by Modulating BCL-2 Expression and Receptor Tyrosine Kinase Signaling in Glioma Cells

Guo Z, Chen Q, Liu B, Tian D, Zhang S, Li M

PURPOSE: Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) are an inhibitor of receptor tyrosine kinases (RTKs) that was discovered in recent years, and many studies showed that LRIG1 is a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer

Lim JU, Woo IS, Jung YH, Byeon JH, Park CK, Kim TJ, Kim HR

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer

Kang S, Ju W, Kim JW, Park NH, Song YS, Kim SC, Park SY, Kang SB, Lee HP

  • KMID: 1094158
  • Exp Mol Med.
  • 2006 Jun;38(3):320-324.
ERCC1 is a DNA repair gene and has been associated with resistance to DNA damaging agents. In this study we hypothesized that a polymorphism of ERCC1 Asn118Asn (C->T) might affect...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Novel EGFR-TK Inhibitor EKB-569 Inhibits Hepatocellular Carcinoma Cell Proliferation by AKT and MAPK Pathways

Kim H, Lim HY

Epidermal growth factor receptor (EGFR)-targeted therapies have been effective in some cancers, but not in hepatocellular carcinoma (HCC). The aim of this study was to investigate the drug potential to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Rare Frameshift Mutation Cys475Tyrfs*11 in the BCR/ABL Kinase Domain Contributes to Imatinib Mesylate Resistance in 2 Korean Patients with Chronic Myelogenous Leukemia

Park SH, Chi HS, Kwon MR, Cho YU, Jang S, Park CJ

  • KMID: 2434491
  • Ann Lab Med.
  • 2012 Nov;32(6):452-454.
No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib

Kang D, Han Z, Oh GH, Joo Y, Choi HJ, Song JJ

PURPOSE: Sorafenib, a multikinase inhibitor, is the standard therapy for patients with advanced-stage hepatocellular carcinoma (HCC). However, resistance develops to the treatment, therefore, we tried to unravel the underlying mechanism...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Salvage Chemotherapy after Gemcitabine Failure in Patients with Advanced Pancreatic Cancer: Survival Benefit in Selected Patients

Lee JL, Kim YT

  • KMID: 783035
  • Korean J Gastroenterol.
  • 2008 Jul;52(1):59-63.
No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Relationship between In Vitro Chemosensitivity assessed with MTT Assay and Clinical Outcomes in 103 Patients with Acute Leukemia

Jun KR, Jang S, Chi HS, Lee KH, Lee JH, Choi SJ, Seo JJ, Moon HN, Im HJ, Park CJ

BACKGROUND: Cellular drug resistance is supposed to play a major role in chemotherapy failure or relapse. The purpose of this study was to analyze the relationship between in vitro...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Human Telomerase Reverse Transcriptase (hTERT): A Target Molecule for the Treatment of Cisplatin-resistant Tumors

Park YP, Kim KD, Kang SH, Yoon DY, Park JW, Kim JW, Lee HG

BACKGROUND: Human telomerase reverse transcriptase (hTERT) is a catalytic enzyme that is required for telomerase activity (TA) and cancer progression. Telomerase inhibition or inactivation increases cellular sensitivity to UV irradiation,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines

Kim SH, Ho JN, Jin H, Lee SC, Lee SE, Hong SK, Lee JW, Lee ES, Byun SS

PURPOSE: The mechanism of resistance to cisplatin during treatment of bladder cancer (BC) has been a subject of intense investigation in clinical research. This study aims to identify candidate genes...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Concomitant AID Expression and BCL7A Loss Associates With Accelerated Phase Progression and Imatinib Resistance in Chronic Myeloid Leukemia

Yu N, Shin S, Choi JR, Kim Y, Lee KA

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr